Pharmacokinetics and pharmacodynamics in antibiotic dose optimization

被引:40
|
作者
Sy, Sherwin K. B. [1 ,2 ]
Zhuang, Luning [1 ,3 ]
Derendorf, Hartmut [1 ]
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
[2] Univ Estadual Maringa, Postgrad Program Biostat, Maringa, Parana, Brazil
[3] US FDA, Div Pharmacometr, Off Clin Pharmacol, Ctr Drug Evaluat & Res, Silver Spring, MD USA
关键词
antibiotics; in vitro models; PK-PD modeling; translational research; CRITICALLY-ILL PATIENTS; COMMUNITY-ACQUIRED PNEUMONIA; INFECTIOUS-DISEASES-SOCIETY; PARA-AMINOSALICYLIC ACID; MUTANT SELECTION WINDOW; STAGE RENAL-DISEASE; PSEUDOMONAS-AERUGINOSA; IN-VITRO; BETA-LACTAMASE; POPULATION PHARMACOKINETICS;
D O I
10.1517/17425255.2016.1123250
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Identifying the optimized dosing regimen and algorithm is critical in the development of antibiotics. Suboptimal regimens and inappropriate choice of drug give rise to drug-resistant bacteria which have limited the therapeutic utility of many commercially available antimicrobial agents. Strategies to optimize therapy of antimicrobial candidates to speed up the development process are urgently needed.Areas covered: We examined pharmacokinetics and pharmacodynamics of antimicrobial agents with modeling and simulation approaches. The approach that is based on minimum inhibitory concentration to evaluate antimicrobial dosing strategy is widely utilized in drug development. The modeling approach utilizing information from time-kill kinetic studies is a tool that can provide more information on the time-course of bacterial response to a particular dosing regimen. Animal studies of dosing regimens that mimic human pharmacokinetics are another option to evaluate antimicrobial efficacy. Empirical, semi-mechanistic and mechanistic models of bacterial dynamics and development of drug resistance in response to drug therapy are discussed.Expert opinion: Both theories and applications of these approaches provide an overall understanding of how the tools can streamline drug development process and help make crucial decisions. Many opportunities and potentials are presented to incorporate more rigorous integration of PK-PD modeling approaches even at preclinical stage to extrapolate to clinical settings, thus enabling successful trials and optimizing dosing strategies in relevant populations where the drug is mostly used.
引用
收藏
页码:93 / 114
页数:22
相关论文
共 50 条
  • [41] The Effect Of Exercise On Pharmacodynamics And Pharmacokinetics Of A Single Dose Of Unfractionated Heparin
    Stuhr, Liva K.
    Feinberg, Joshua B.
    Christoffersen, Thea
    Dimopoulos, Konstantinos
    Larsen, Emil L.
    Karstoft, Kristian
    [J]. MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2024, 56 (10) : 152 - 153
  • [42] MULTIPLE-DOSE PHARMACOKINETICS AND PHARMACODYNAMICS OF ADINAZOLAM IN ELDERLY SUBJECTS
    FLEISHAKER, JC
    PHILLIPS, JP
    SMITH, TC
    SMITH, RB
    [J]. PHARMACEUTICAL RESEARCH, 1989, 6 (05) : 379 - 386
  • [43] EVALUATION OF THE PHARMACODYNAMICS AND PHARMACOKINETICS OF RITODRINE WHEN ADMINISTERED AS A LOADING DOSE
    CARITIS, SN
    LIN, LS
    WONG, LK
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1985, 152 (08) : 1026 - 1031
  • [44] Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and gender
    Robson, R
    White, H
    Aylward, P
    Frampton, C
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (06) : 433 - 439
  • [45] Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam
    Norio Yasui
    T. Kondo
    Koichi Otani
    Hanako Furukori
    Sunao Kaneko
    Tadashi Ohkubo
    Takako Nagasaki
    Kazunobu Sugawara
    [J]. Psychopharmacology, 1998, 139 : 269 - 273
  • [46] Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin
    Priskorn, M
    Sidhu, JS
    Larsen, F
    Davis, JD
    Khan, AZ
    Rolan, PE
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (02) : 199 - 202
  • [47] ODANACATIB DOES NOT INFLUENCE THE SINGLE DOSE PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN
    Stoch, S. Aubrey
    Witter, Rose
    Hreniuk, David
    Liu, Chengcheng
    Zajic, Stefan
    Mehta, Anish
    Chandler, Patricia
    Morris, Denise
    Xue, Hongwei
    Denker, Andrew
    Wagner, John A.
    [J]. JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2013, 20 (03): : E312 - E320
  • [48] Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics
    Downes, Kevin J.
    Hahn, Andrea
    Wiles, Jason
    Courter, Joshua D.
    Vinks, Alexander A.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 43 (03) : 223 - 230
  • [49] Liposomal methylprednisolone in rats: Dose-proportionality and chronic-dose pharmacokinetics pharmacodynamics
    Mishina, EV
    Jusko, WJ
    [J]. PHARMACEUTICAL RESEARCH, 1996, 13 (01) : 141 - 145
  • [50] Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions
    Uhl, A
    Czock, D
    Boehm, BO
    Zellner, D
    Mertz, A
    Keller, F
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2002, 27 (04) : 281 - 287